oncodxrx

[oncodxrx]

OncoDxRx’s PGA assay is revolutionary with gene-drug matchmaker capability

OncoDxRx’s PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) innovation will include disruptive technologies, with high-performance liquid biopsy platform supported by big data algorithms.

The Los Angeles-based liquid biopsy company’s PGA assay will provide therapy guidance for those patients currently not responding to targeted treatment as it detects, matches and ranks efficacies of existing anticancer drugs for each individual patient based on his/her own gene expression signature.

The company has developed a set of disruptive technologies that will ensure the test superiority of liquid biopsy in the years ahead. New broad-format panels housing multiple biomarkers will provide unparalleled levels of precision in their drug matching capabilities.

The new platform will generate significantly larger volumes of gene expression data from both tumor and non-tumor tissues. The in silico data processing system (screening, matching, identifying, ranking) will use advanced Big Data algorithm, with intuitive user interfaces to optimise operator workload and provide decision support.

The latest innovations developed by dedicated OncoDxRx scientists for the current and future generations of liquid biopsy will provide the company with a comprehensive roadmap of the circulating cell-free transcriptomics to meet current and future clinical needs, helping to consolidate its position as one of the world’s leading cell-free mRNA company.

[oncodxrx]

OncoDxRx Bringing Disruptive Technologies to Cancer Patients in Need

OncoDxRx discovers new blood tests. The company has developed and validated a one-of-a-kind liquid biopsy technology which is a disruptive and dramatically cost-effective step forward in personalized medicine.

OncoDxRx is completely unique and has the potential to make a giant leap in every stage of cancer management from early detection, treatment selection, MRD to drug discovery. The company has solved the key problems in theranostics that cause the dramatic lack of progress.

All OncoDxRx’s novel tests could be performed on one blood sample and will be targeted at cancers.

Many companies and research groups are looking to deliver in this space. Billions have been spent in the process. What makes OncoDxRx unique is the team’s understanding of why previous efforts failed – and the past 5 years they have spent developing much-needed, disruptive and transformative technologies that can deliver.

To bring the solution to mass market, OncoDxRx is looking to engage strategically with the global healthcare ecosystem and is looking for backing from US stakeholders.

The company’s first product is a blood test called PGA for lung cancer. PGA stands for Patient-derived Gene expression-informed Anti-cancer drug efficacy.

In its first independently blinded validation trial it performed much better than current clinical practice. It holds great promise for treatment decision support, especially for those patients who are currently out of option of targeted therapy or immunotherapy.

Years of R&D work has given the company confidence that these exclusive one-of-a-kind technologies will translate and validate in the clinic. All the key elements – technology, market and team combine into a unique capability which places OncoDxRx at the forefront of the production of new clinically relevant point-of-life diagnostics.

It is safe to say that if OncoDxRx can deliver on this mission – as the company believe they can – it will be transformative for healthcare delivery world-wide. Vast amounts of money can be saved if an effective set of theranostic tests can be developed. The company will literally be saving billions by saving millions.

[oncodxrx]

OncoDxRx's leading-edge blood-based cfmRNA core technology

From personal to personalized

A keystone to drug response biomarkers and central to the PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) platform is high-impact liquid biopsy cell-free mRNA (cfmRNA) profiling – inherent genomic signals within and surrounding a tumor that are characteristic of its underlying biology. Through advanced plasma cfmRNA profiling and computational analysis, an expanding portfolio of cancer type-specific biomarkers accrues within PGA.

Our platform leverages unique gene expression datasets complemented by proprietary data and tools to develop discrete sets of key genes that define cancer types and predict drug response. By reducing the multitude of genes associated with response to discrete key gene set signatures, we enable rapid development of tumor-specific clinical assays. The signatures are platform agnostic, so they are capable of being deployed on established commercial instruments.

Our ability to identify and reduce to practice a select gene panel that defines cancer types and predicts drug response underlies our core patents and proprietary position.

In addition to core tumor biology genotyping, which often include characteristic immune profiles, a deep immunogenomic capability is essential to fully exploring the tumor in the context of its associated microenvironment. OncoDxRx’s proprietary cfmRNA technology is comprised of unparalleled immunogenomic profiling datasets in circulation involving diverse neoantigen prediction, highly curated and proprietary immune gene signatures.

Our blood-based cfmRNA-driven informatics greatly expands the ability to discover therapeutic tumor neoantigens, as well as identify biomarkers for monitoring minimal residual disease (MRD) in cancer. It goes beyond the use of gene expression to develop unique response signatures and unlocks underlying RNA sequence information that leads to new drug targets. In addition to discovering new therapeutic antigens, we can apply our cfmRNA core technology to new and existing datasets to identify improved biomarkers of immunotherapy response.

[oncodxrx]

How OncoDxRx’s PGA Reveals What Others Miss

The PGA difference: Revealing the uncovered and unpredicted

OncoDxRx’s highly sensitive and specific cell-free mRNA-based PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) assays, capable of predicting drug efficacy for patients not responding to targeted therapy, was particularly important for the precision oncology care of this non-responder population.

[oncodxrx]

OncoDxRx’s Cell-Free Transcriptomic Pipelines Capture More Particulars, Reveal More Grandeur

From gene expression analyses to drug efficacy results, OncoDxRx’s technologies are compiling richer data sets and generating deeper oncological insights

A patient’s genome contains information about that patient’s disease predispositions and drug responses. However, that better information about disease risks and drug responses could be gleaned from the transcriptome. Although there are only so many transcript-encoding genes, the intricacies of RNA expression generate various kinds of gene expression information in abundance.

Information about disease-induced modifications, splicing isoforms, expression changes, and gene regulation complexity can inform predictions of what will happen in the body, in the context of the body and the environment. OncoDxRx suggests that a transcriptomics approach—one that would involve monitoring of not just one gene at a time, but hundreds—could generate valuable clinical insights.

OncoDxRx emphasized the importance of messenger RNA (mRNA) as drug targets like COVID-19. After noting that the field of vaccine-based mRNA medicine had enjoyed explosive growth over the last two to three years, the company declared that the growth would go on, and that more data would be produced more quickly. And after emphasizing that liquid biopsy cell-free mRNA (cfmRNA) technology can identify tumor biomarkers and drug targets independently or in combination with other omics technologies, OncoDxRx gave one more prediction: “We are entering the most interesting era in medical research ever.”

The transcriptomics wave and the spatial biology wave are overlapping. The result: an unusually impressive example of functional genome roadmap.

And though it’s still early days for cfmRNA—and challenges like large amounts of data, cost, accessibility, and more, will all need to be ironed out—the excitement lies in the technology’s ability to uncover new oncological understandings that would otherwise remain out of reach.